PSNL News and Press, Personalis Inc. From 01/26/21

Personalis (PSNL) slumped 3.6% in after hours trade after commencing an underwritten public offering of $150M; underwriters granted 30-day option to purchase up to an additional $22.5 M of common stock.Offer size, terms have not yet been disclosed. For further details see: Per...

A recap for my 20/20 Vision is offered for my readers. I will share my concerns about the current market conditions. A look back at companies I have written articles about over the last three years - 2018-2020. The good, the bad and the ugly! For further details see: Fin...

With so much hype around coronavirus vaccine stocks, it was easy to miss Personalis (NASDAQ: PSNL) , which became a 10-bagger after the market crash last year. Personalis is a biotech that competes with Guardant Health (NASDAQ: GH) and Adaptive Biotechnologies (NASDAQ:...

Personalis (PSNL) reports Q4 preliminary revenue of ~20.2M, vs $18.2M previously, representing an increase of 11%. For the FY 2020, revenue is estimated to be ~$78.6M compared with $65.2M for 2019, representing an increase of 21%.Preliminary revenue from biopharma and all other...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2020. Personalis estimates revenue of approximately $20.2 million for the fourth ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that management will present at the 23rd Annual Needham Virtual Growth Conference on Wednesday, January 13, 2021 at 2:45 p.m. Eastern Time. About Personalis, Inc. Personalis, Inc. is a...

Personalis ([[PSNL]] +2.9%) announces the launch of its proprietary Neoantigen Presentation Score (‘NEOPS’).NEOPS combines the tumor genomic and immune-related analytics of the Personalis® NeXT Platform™ to create a composite biomarker. NEOPS leverages Personalis...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of its proprietary Neoantigen Presentation Score (NEOPS). NEOPS combines analysis from Personalis’ state-of-the-art tumor neoantigen prediction tool, SHERPA™, with mechani...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of its Systematic HLA Epitope Ranking Pan Algorithm (SHERPA), the company’s proprietary, machine learning-based tool for the comprehensive identification and characterization of ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, announced today that it has delivered the 100,000th whole human genome sequence dataset to the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). Although Personalis h...